SCHEMBL1406757

SCHEMBL1406757

Cc1ccc(-c2cc(C(=O)C=Cc3ccc(C(=O)O)cc3)cc(OCc3ccccc3)c2C(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.48
MAPT P10636 3/20 0.47
CYP3A4 P08684 2/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
BLM P54132 1/20 0.47
CASP7 P55210 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
TNFRSF1A P19438 1/20 0.47
ALDH1A1 P00352 2/20 0.45
CYP1B1 Q16678 1/20 0.45
HPGD P15428 1/20 0.45
RXRA P19793 3/20 0.44
RXRB P28702 3/20 0.44
RXRG P48443 3/20 0.44
PTGER1 P34995 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406578 1.00 MAOB (0.48) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL1406530 0.93 TP53 (0.53) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL1406756 0.93 TP53 (0.53) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL6423156 0.91 TNFRSF1A (0.41) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL6423150 0.89 TNFRSF1A (0.39) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL1406702 0.86 TNFRSF1A (0.52) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL1406700 0.86 TNFRSF1A (0.52) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL1406379 0.86 MAPT (0.48) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL1406382 0.86 MAPT (0.48) MAOBMAPTCYP3A4TP53ALOX15
SCHEMBL6423154 0.85 MAOB (0.40) MAOBMAPTCYP3A4ABCG2TNFRSF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG MAOB 1897/4885MAPT 4711/4885CYP3A4 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.